Claes Wahlestedt, M.D., Ph.D., an internationally recognized researcher of novel drug therapies for neuropsychiatric disorders and epigenetics, is the director of the Center for Therapeutic Innovation and associate dean for therapeutic innovations at the John P. Hussman Institute for Human Genomics. A founding faculty member and professor of neuroscience and molecular therapeutics at the Florida campus of The Scripps Research Institute.

14 year track record in the identification and validation of new drug targets, discovering initial chemical leads, and in advancing those leads through pre-clinical discovery. As project leader he advances multi-disciplinary project teams from concept to pre-clinical toxicology. With a background in Chemistry and Biochemistry, he also leads chemistry teams in design, chemical synthesis and optimization.
22 scientific publications, 26 patents.

Co-Founded Epigenetix Inc, Curna Inc (sold to Opko 2011) , Sumpraxis and Technisource ( took public 1987 sold 2002) . In all cases worked at CEO level and intimately involved in Technology and Strategy.
Specialties: Strategic Investment, Biotech, Project Planning, Business Development, Scientific Software Applications.

Working to make the world better by starting and funding companies.

Founding member of the Center for Therapeutic Innovation.

Specialties: G protein coupled receptor signaling, epigenetics, cell biology, drug discovery, writing

Dr. Ayad is a cell biologist by training and has worked on enzymatic regulation of mitotic cell divisions in neuronal precursors. Dr. Ayad received his Ph.D. degree from Yale Medical School in 1998 and completed his postdoctoral training from Harvard Medical School in 2004. He served as an assistant professor at the Scripps Research Institute in Jupiter, Florida prior to joining UofM.

CFO 11 years for NASDAQ companies, including reverse merger and secondary offering.
CFO of public and private companies in bio-tech, medical device, consumer goods, and other industries